Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide, ixazomib, and dexamethasone with or without cyclophosphamide in relapsed/refractory multiple myeloma
2014-001757-16Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pomalidomide, ixazomib, dexamethasone and cyclophosphamide in multiple myeloma (MM) (2 arms), sponsored by GWT-TUD. Primary endpoint: Overall response rate to PId. Started Jul 2016; status: completed.
02
Drugs
pomalidomideixazomibdexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-001757-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001757-16.